Funding The National Key Research and Development Program of China (2020YFA0908200 and 2020YFA0710800), the Key Program of the National Natural Science Foundation of China (81930043 and 82330055), the National Natural Science Foundation of China (T2225003, 82001719, 52073060, and 61927805), the Natural Science Foundation of Jiangsu (BE2018707), the Nanjing Medical Science and Technique Development Foundation (ZKX21019) and the Clinical Trials from Nanjing Drum Tower Hospital (2022-LCYI-ZD-01)
Cirillo, V
Li Q, Zhu X, Xie Y, Zhong Y (2021) o-Vanillin, a promising antifungal agent, inhibits Aspergillus flavus by disrupting the integrity of cell walls and cell membranes
Absence of Human Data: The most critical gap remains the absence of large, well-designed human clinical trials providing conclusive evidence of weight loss
For individuals with pernicious anaemia or a condition that prevents B12 absorption, injections are medically necessary because oral supplementation will not be absorbed effectively
Thats the real danger not BPC-157 itself, but whats in the vial
